Does Donepezil, Used for Cognitive Impairment in Alzheimer's, Also Benefit Patients Receiving Brain Radiotherapy?

The American Journal of Clinical Oncologypublished research showing that donepezil significantly benefited certain cognitive and functional abilities, such as memory, motor function, and manual dexterity, in patients receiving brain radiotherapy, particularly those with greater cognitive impairment.
Brain radiation treatment is known to impair cognitive functions in a substantial proportion of patients. Radiation particularly affects the hippocampus, a brain region involved in learning, memory, and mood. Fewer memory problems with hippocampal-sparing radiotherapy support this. Although recent advances and methods such as stereotactic radiotherapy have minimized these side effects, they remain significant. Studies are therefore investigating ways to reduce them. Donepezil, used for Alzheimer's disease, is among the drugs being tested.
After the cholinergic system was found to contribute to Alzheimer's progression, drugs acting through the acetylcholine enzyme began to be used in treatment. The most successful to date have been acetylcholinesterase inhibitors, including the commonly used donepezil. These drugs prevent the breakdown of the acetylcholine enzyme released into the surrounding environment and increase its amount, thereby slowing cognitive and functional loss in Alzheimer's. Animal experiments have shown that brain radiotherapy adversely affects the cholinergic system involved in motor activity and the hippocampus involved in memory. This suggested that donepezil might benefit functions such as memory and motor activity in patients receiving brain radiotherapy, and an important study on this subject was recently published.
In the study; patients receiving brain radiotherapy were evaluated 6 months afterward: 198 patients were divided into 2 groups. Some received donepezil regularly each day, while others did not. Cognitive and functional tests assessing memory, language, attention, and motor functions were performed before starting donepezil, 3 months afterward, and at 6 months. There was no significant difference initially, but in the donepezil group after 6 months, certain abilities such as memory, motor function, and manual dexterity were significantly better, particularly in those with greater cognitive impairment. Donepezil also caused no serious side effects and was well tolerated.
In conclusion; donepezil did not improve all cognitive functions in all patients receiving brain radiotherapy. However, it significantly benefited certain cognitive and functional abilities, including memory, motor function, and manual dexterity, particularly in those with greater cognitive impairment. It was also very well tolerated. This study is an extremely important development for preserving these patients' quality of life, but further research is needed to support it.
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.